Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently.

Methods

In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety.

Results

A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups.

Conclusions

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728. opens in new tab.)

Click here to read the full journal article.

Source: New England Journal of Medicine

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

Cities Around the World Need to Prepare for Innovations in Dementia, According to a New Report from the Global Coalition on Aging (GCOA), Alzheimer’s Disease International (ADI) and Lien Foundation

New York, NEW YORK (October 8, 2020) - Today, the Global Coalition on Aging (GCOA) and Alzheimer’s Disease International (ADI), in partnership with Singapore’s Lien Foundation, will present findings from the 2020 Dementia Innovation Readiness Index showing that cities have largely failed to support innovation in dementia comprehensively, though bright spots exist.

New Report from Global Coalition on Aging Calls on Policy and Health System Leaders to Advance Gender Equality and Economic Growth by Empowering Women to Achieve Healthy Aging

New York, New York (November 9, 2020) – Today, the Global Coalition on Aging (GCOA) released Empowering Women for Healthy Aging: Key Policy Actions to Address Health Challenges Across the Life Course, a report calling for new policy conversations and actions to spur economic growth and social equity by addressing women’s health that also advances women’s rights.

Joint Statement on COVID-19 Vaccines & Older Adults

As WHO, CEPI, and Gavi meet and consider how best to manage the planning and deployment of a COVID-19 vaccine, we feel the voice of older adults, one of the most vulnerable, important, and essential groups should feature prominently in the COVAX process.

2020 Silver Economy Forum-China Kick-Off Event

The Global Coalition on Aging (GCOA) is pleased to announce that the 2020 Silver Economy Forum will kick off on July 29, followed by a series of virtual events in September. The special preview event, Silver Economy Sustainability in China and Globally: Lessons from COVID-19, will take place on July 29, at 8:00 AM EDT / 2:00 PM CEST / 8:00 PM CST.

New Report From the American Federation for Aging Research and the Global Coalition on Aging Highlights Adult Vaccination as Critical Lever for Healthy Aging

New York, NEW YORK (July 14, 2020) – The American Federation for Aging Research (AFAR) and the Global Coalition on Aging today released a report, Adult Vaccinations: Opportunities for Action, Barriers to Engagement, Paths to Healthier Aging. The new report shares insights from an expert symposium hosted by the two organizations in late 2019 on the urgency of vaccinations for adults to promote healthy aging.